Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its blockbuster therapy Keytruda to allow its use as a first-line combination ...
Adverse reactions were generally similar to those in other patients receiving Keytruda and chemotherapy, said Merck. "We're pleased to offer a new first-line treatment option for adult patients ...